New Delhi: Bharat Biotech on Tuesday said it will continue the steady supply of its COVID-19 vaccine Covaxin, adding the jab has been directly supplied to 18 states since May 1.
The states include Andhra Pradesh, Delhi, Bihar, Gujarat, Haryana, Uttar Pradesh and West Bengal, the Hyderabad-based firm added.
“COVAXIN has been directly supplied to 18 states since May 1st. Unflinching in our efforts, we will continue the steady supply of our #vaccine,” Bharat Biotech said in a tweet.
The company is supplying its vaccine to Andhra Pradesh, Assam, Bihar, Chhattisgarh, Delhi, Gujarat, Haryana, Jammu & Kashmir, Jharkhand, Karnataka, Madhya Pradesh, Maharashtra, Odisha, Tamil Nadu, Tripura, Telangana, Uttar Pradesh and West Bengal.
Bharat Biotech has commenced direct supply of Covaxin with effect from May 1 to several states based on the allocations received by the central government, the company’s Joint Managing Director Suchitra Ella had earlier said.
On April 29, Bharat Biotech had announced a cut in the price of Covaxin for states to Rs 400 per dose from the earlier Rs 600.
This followed widespread criticism of its pricing policy as it sold Covaxin to the central government at Rs 150 per dose.
India has expanded its COVID-19 vaccination drive by allowing its large 18-plus population to get inoculated from May 1.
(Follow Money9 for latest Personal finance stories and Market Updates)
In a joint term insurance plan, not many insurers provide add-on covers along with a primary joint life insurance plan
So far, there is some evidence of a change in consumption pattern based on high-frequency consumption indicators for consumers in advanced economies
We should see more small investors take to ETF and passive investing in certain categories such as large-cap equities where active funds are lagging
Both Centre and the states are overly dependent on petroleum taxes. They may not ease their grip on them